Approval Supports Revenue Growth and Margin Expansion Opportunity, and Substantially Increases Peak Production Output Capacity First U.S. Regulatory Approval of Innovative IG Yield Enhancement Process Highlights ADMA's Uniquely Efficient Internal R&D Engine, Spanning Production and Product Development Capabilities Anticipate Approximately 20% Production Output Enhancement from Same Starting Plasma Volume About ADMA Biologics, Inc. (ADMA) ADMA Biologics is a U.S. based, end-to-end commercial biopharmaceutica ...